静脉-动脉体外膜氧合挽救脓毒症诱导的心源性休克:回顾性多中心国际队列研究
这项回顾性、多中心、国际队列研究比较了82例接受VA-ECMO的脓毒症休克患者与130例未接受ECMO的对照(来自三个大型脓毒症休克数据库)。所有患者均有严重心肌功能障碍(心脏指数≤3 L/min per m2或LVEF≤35%)和严重血流动力学受损(正性肌力药评分≥75 μg/kg per min或乳酸酸血症≥4 mmol/L)。VA-ECMO组基线病情更重,但90天生存率显著更高(60% vs 25%,RR for mortality 0.54,95%CI 0.40-0.70;p<0.0001);倾向评分加权后仍与生存改善相关(51% vs 14%,adjusted RR for mortality 0.57,95%CI 0.35-0.93;p=0.0029)。作者结论认为VA-ECMO与生存大幅改善相关,但不能排除未测量混杂。
要点
- 严重脓毒症诱导心源性休克(心脏指数≤3 L/min per m2或LVEF≤35%,正性肌力药评分≥75 μg/kg per min或乳酸≥4 mmol/L)患者接受VA-ECMO后90天生存率60% vs 对照25%(RR for mortality 0.54,95%CI 0.40-0.70)。
- 倾向评分加权后VA-ECMO仍与生存改善相关(51% vs 14%,adjusted RR for mortality 0.57,95%CI 0.35-0.93;p=0.0029)。
- VA-ECMO组乳酸和儿茶酚胺清除显著增强。
- 49例ECMO存活者中,最大中心治疗的32例在1年随访时报告Short Form-36评估的健康相关生活质量满意。
- 作者结论认为VA-ECMO与生存大幅改善相关,但不能排除未测量混杂。
适用人群与场景
- 年龄≥18岁的脓毒症休克患者,来自五个学术ECMO中心(VA-ECMO组82例)和三个大型脓毒症休克数据库(对照组130例)。
- 纳入条件:严重心肌功能障碍(心脏指数≤3 L/min per m2或LVEF≤35%)和严重血流动力学受损(正性肌力药评分≥75 μg/kg per min或乳酸酸血症≥4 mmol/L)。
- VA-ECMO组基线病情更重:平均心脏指数1.5 vs 2.2 L/min per m2,LVEF 17% vs 27%,正性肌力药评分279 vs 145 μg/kg per min,乳酸8.9 vs 6.5 mmol/L,SOFA评分17 vs 13(每项比较p<0.0001)。
诊断标准与关键阈值
- 严重心肌功能障碍:心脏指数≤3 L/min per m2或LVEF≤35%。
- 严重血流动力学受损:正性肌力药评分≥75 μg/kg per min或乳酸酸血症≥4 mmol/L。
处置流程与药物剂量
- VA-ECMO用于对常规治疗无效的脓毒症诱导心源性休克。
研究设计与关键结果
- 回顾性、多中心、国际队列研究:VA-ECMO组82例,对照组130例(未接受ECMO,来自三个大型脓毒症休克数据库)。
- 主要终点90天生存率:VA-ECMO组60% vs 对照组25%(RR for mortality 0.54,95%CI 0.40-0.70;p<0.0001)。
- 倾向评分加权后:VA-ECMO组51% vs 对照组14%(adjusted RR for mortality 0.57,95%CI 0.35-0.93;p=0.0029)。
- VA-ECMO组乳酸和儿茶酚胺清除显著增强。
- 49例ECMO存活者中,32例在最大中心治疗者在1年随访时报告Short Form-36评估的健康相关生活质量满意。
证据类型、等级与局限
- 证据类型:回顾性、多中心、国际队列研究。
- 局限:尽管进行了仔细的倾向评分加权分析,仍不能排除未测量混杂。
对床旁实践的改变
- 作者认为,对于严重脓毒症诱导心源性休克患者,VA-ECMO与生存大幅且显著的改善相关(与未接受ECMO的对照相比)。
- 作者指出,尽管进行了仔细的倾向评分加权分析,仍不能排除未测量混杂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with sepsis-induced cardiomyopathy with cardiogenic shock have a high mortality. This study assessed venoarterial extracorporeal membrane oxygenation (VA-ECMO) support for sepsis-induced cardiogenic shock refractory to conventional treatments.
METHODS: In this retrospective, multicentre, international cohort study, we compared outcomes of 82 patients (aged ≥18 years) with septic shock who received VA-ECMO at five academic ECMO centres, with 130 controls (not receiving ECMO) obtained from three large databases of septic shock. All patients had severe myocardial dysfunction (cardiac index 3 L/min per m2 or less or left ventricular ejection fraction [LVEF] 35% or less) and severe haemodynamic compromise (inotrope score at least 75 μg/kg per min or lactic acidaemia at least 4 mmol/L) at time of inclusion. The primary endpoint was survival at 90 days. A propensity score-weighted analysis was done to control for confounders.
FINDINGS: At baseline, patients treated with VA-ECMO had more severe myocardial dysfunction (mean cardiac index 1·5 L/min per m2vs 2·2 L/min per m2, LVEF 17% vs 27%), more severe haemodynamic impairment (inotrope score 279 μg/kg per min vs 145 μg/kg per min, lactataemia 8·9 mmol/L vs 6·5 mmol/L), and more severe organ failure (Sequential Organ Failure Assessment score 17 vs 13) than did controls, with p<0·0001 for each comparison. Survival at 90 days for patients treated with VA-ECMO was significantly higher than for controls (60% vs 25%, risk ratio [RR] for mortality 0·54, 95% CI [0·40-0·70]; p<0·0001). After propensity score weighting, ECMO remained associated with improved survival (51% vs 14%, adjusted RR for mortality 0·57, 95% CI [0·35-0·93]; p=0·0029). Lactate and catecholamine clearance were also significantly enhanced in patients treated with ECMO. Among the 49 survivors treated with ECMO, 32 who had been treated at the largest centre reported satisfactory Short Form-36 evaluated health-related quality of life at 1-year follow-up.
INTERPRETATION: Patients with severe sepsis-induced cardiogenic shock treated with VA-ECMO had a large and significant improvement in survival compared with controls not receiving ECMO. However, despite the careful propensity-weighted analysis, we cannot rule out unmeasured confounders.
参考来源
- Bréchot N, Hajage D, Kimmoun A, et al. Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study. Lancet. 2020. PMID: 32828186. doi:10.1016/S0140-6736(20)30733-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。